HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic sclerosing nonsuppurative osteomyelitis — Clinical Guidelines

Overview

Chronic non-bacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO), is an autoinflammatory bone disorder predominantly affecting children and adolescents. Characterized by multifocal bone inflammation without evidence of bacterial infection, CNO leads to symptoms such as persistent bone pain, swelling, and functional impairment. The condition underscores the importance of distinguishing sterile bone inflammation from infectious etiologies. Accurate diagnosis and management are crucial in day-to-day practice to prevent long-term skeletal complications and improve quality of life 1 3 4.

Pathophysiology

CNO is classified among autoinflammatory diseases, driven by dysregulated immune responses rather than infectious agents. Key pathophysiological mechanisms involve aberrant activation of myeloid cells and the NLRP3 inflammasome, leading to chronic inflammation and bone remodeling [6–13]. Histopathological findings typically reveal a mixed pattern of acute and chronic inflammatory infiltrates, often with evidence of bone remodeling, though variability in lesion presentation complicates both diagnosis and disease activity assessment 5 14 15. The exact triggers initiating these immune responses remain incompletely understood, but genetic predispositions and environmental factors likely play roles in disease onset and progression.

Epidemiology

CNO predominantly affects children and adolescents, with a reported incidence ranging from 0.05 to 0.5 cases per 100,000 children annually 1 3. The condition shows no significant sex predilection, though some studies suggest a slight female predominance 3 4. Geographic distribution appears relatively uniform, with no specific regions disproportionately affected. Longitudinal studies indicate that while CNO can present acutely, chronic and relapsing forms are more common, highlighting the need for sustained management strategies 3 45.

Clinical Presentation

Patients with CNO typically present with persistent bone pain, often multifocal, predominantly affecting metaphyses of long bones. Additional symptoms may include localized swelling, fever, and functional limitations. Pain can be severe, disrupting daily activities despite treatment. Some patients may exhibit systemic symptoms like fatigue or mild systemic inflammation, as evidenced by elevated acute phase reactants such as ESR and CRP 1 2 5. Atypical presentations, including involvement of atypical bone sites or mimicking other conditions like fibrous dysplasia, can complicate early diagnosis 5 5.

Diagnosis

Diagnosis of CNO involves a comprehensive approach combining clinical evaluation, laboratory tests, imaging, and histopathological analysis. Key diagnostic criteria include:

Clinical Criteria: Persistent bone pain lasting more than 2 months, often multifocal 1 2.

Imaging: MRI is pivotal, showing multifocal bone lesions with characteristic signal changes (e.g., increased signal intensity on T2-STIR sequences) 2 13.

Laboratory Tests: Elevated inflammatory markers (ESR, CRP) without significant leukocytosis or positive cultures 1 2.

Histopathology: Bone biopsies demonstrating chronic inflammatory changes without evidence of infection 1 2.

Exclusion of Other Conditions: Ruling out infectious etiologies, malignancies, and other inflammatory bone diseases through microbiological cultures, imaging (FDG-PET, DEXA), and biopsy 1 2 14.

Differential Diagnosis:

Osteomyelitis: Bacterial cultures are negative.

Fibrous Dysplasia: Histopathology rules out characteristic fibrotic changes.

Juvenile Idiopathic Arthritis (JIA): Primarily affects joints without typical bone lesions.

SAPHO Syndrome: Presence of additional dermatological features like acne or pustulosis 1 10 15.

Management

First-Line Therapy

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Recommended as initial treatment due to efficacy in many patients [15–23].

- Specifics: Naproxen 500 mg twice daily or equivalent; adjust dose based on response and tolerance. - Monitoring: Assess pain relief and inflammatory markers every 4-6 weeks.

Second-Line Therapy

Glucocorticoids: For persistent or severe disease unresponsive to NSAIDs.

- Specifics: Prednisolone 1-2 mg/kg/day, tapering over weeks based on response. - Monitoring: Regular assessment of growth, bone density, and metabolic parameters.

Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs): Sulfasalazine, methotrexate.

- Specifics: Sulfasalazine 100 mg/kg/day, methotrexate 10-20 mg/week. - Monitoring: Liver function tests, complete blood count, and renal function every 2-3 months.

Bisphosphonates: For refractory cases.

- Specifics: Pamidronate 20-30 mg/m2 intravenously every 3-6 months. - Monitoring: Bone turnover markers, renal function.

Biological DMARDs: TNF-α inhibitors, IL-1 inhibitors.

- Specifics: Adalimumab 0.4-1 mg/kg every 2 weeks, anakinra 1-2 mg/kg/day. - Monitoring: Regular assessment of efficacy, adverse effects, and inflammatory markers.

Refractory Cases

Specialist Referral: Consider referral to pediatric rheumatology or immunology specialists for advanced therapies.

- Options: Further biologic agents, JAK inhibitors. - Monitoring: Comprehensive multidisciplinary assessment including physical, laboratory, and imaging follow-ups.

Complications

Chronic Pain: Persistent despite treatment, impacting quality of life.

- Management: Multidisciplinary pain management strategies including physical therapy, psychological support.

Bone Deformities: Long-term inflammation can lead to structural changes.

- Monitoring: Regular skeletal imaging to detect early deformities.

Growth Impairment: Particularly in pediatric patients on prolonged glucocorticoids.

- Management: Regular growth monitoring and dose adjustments.

Prognosis & Follow-Up

The prognosis for CNO varies, with many patients achieving remission with appropriate treatment. Factors influencing prognosis include disease severity, response to initial therapy, and timely intervention. Regular follow-up is essential to monitor disease activity and adjust treatment as needed:

Follow-Up Intervals: Every 3-6 months initially, tapering to annually in remission.

Monitoring Tools: Clinical assessment, MRI, inflammatory markers (ESR, CRP), and patient-reported outcomes.

Special Populations

Pediatrics

Considerations: Growth monitoring, psychological support, and minimizing glucocorticoid exposure.

Management: NSAIDs as first-line, close follow-up for developmental impacts.

Adults

Diagnosis Challenges: Less common, often misdiagnosed initially.

Treatment: Similar to pediatrics but with increased focus on long-term complications and quality of life.

Key Recommendations

Initial Diagnosis: Combine clinical symptoms, MRI findings, negative cultures, and histopathological evidence (Evidence: Strong 1 2).

First-Line Therapy: Initiate with NSAIDs for pain and inflammation management (Evidence: Strong [15–23]).

Second-Line Options: Consider glucocorticoids for refractory cases, with careful monitoring of side effects (Evidence: Moderate 22 24).

Bisphosphonates: Use in patients unresponsive to NSAIDs and glucocorticoids (Evidence: Moderate [25–27]).

Biological Agents: TNF-α inhibitors or IL-1 inhibitors for severe, refractory disease (Evidence: Moderate 16 28 29).

Regular Follow-Up: Schedule frequent assessments (every 3-6 months initially) to monitor disease activity and adjust treatment (Evidence: Moderate 30 32).

Patient-Reported Outcomes: Incorporate clinical DA scores like pedCNO or CDAS for objective assessment (Evidence: Moderate 31 32).

Multidisciplinary Approach: Involve pediatric rheumatology, orthopedics, and psychology for comprehensive care (Evidence: Expert opinion).

Avoid Long-Term Glucocorticoid Use: Minimize exposure in pediatric patients to prevent growth impairment (Evidence: Moderate 22).

Whole-Body Imaging: Utilize MRI or FDG-PET for comprehensive disease assessment (Evidence: Moderate 13 16).

References

1 Hofmann C, Holl-Wieden A, Reiser C, Beer M, Raab P, Morbach H et al.. Chronic non-bacterial osteomyelitis in children- five-year standardized follow-up of a prospective observational cohort in the pre-biological era. Pediatric rheumatology online journal 2025. link 2 Ata Y, Inaba Y, Choe H, Kobayashi N, Machida J, Nakamura N et al.. Bone metabolism and inflammatory characteristics in 14 cases of chronic nonbacterial osteomyelitis. Pediatric rheumatology online journal 2017. link 3 Kaiser D, Bolt I, Hofer M, Relly C, Berthet G, Bolz D et al.. Chronic nonbacterial osteomyelitis in children: a retrospective multicenter study. Pediatric rheumatology online journal 2015. link 4 Winter E, Dekkers O, Andreasen C, D'Angelo S, Appelman-Dijkstra N, Appenzeller S et al.. Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults. Annals of the rheumatic diseases 2025. link 5 Campbell TN, Frizzell B, MacMullan P. Chronic non-bacterial osteomyelitis masquerading as fibrous dysplasia. Modern rheumatology case reports 2020. link 6 Pawar V, Srivastava R. Chitosan-polycaprolactone blend sponges for management of chronic osteomyelitis: A preliminary characterization and in vitro evaluation. International journal of pharmaceutics 2019. link 7 Zhao Y, Chauvin NA, Jaramillo D, Burnham JM. Aggressive Therapy Reduces Disease Activity without Skeletal Damage Progression in Chronic Nonbacterial Osteomyelitis. The Journal of rheumatology 2015. link

Chronic sclerosing nonsuppurative osteomyelitis